Limits...
Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: The basophil activation test showing CD63 up regulation could be a specific and sensitive in vitro complementary text to the in vivo autologous serum skin test for the activity assessment of the patients suffering autoimmune chronic spontaneous urticaria. The aim of this study is to define the basophil activation test as a useful tool in clinical practice in order to identify those patients with more active disease.

Methods: We screened 139 patients (96 women) diagnosed of chronic spontaneous urticaria using simultaneously autologous serum skin test and basophil activation test and their relationship with disease activity.

Results: Positive autologous serum skin test was found in 56.8%; from them, 31.6% were basophil activation test positive. Negative autologous serum skin test result was found in the 43.2% of the sample that showed negative CD63 expression results in all cases, except one. Patients with positive autologous serum skin test and positive CD63 by basophil activation test showed significant higher Urticaria Activity Score of 7 days (P = 0.004) and of 3 weeks (P = 0.001) than patients with positive autologous serum skin test and negative CD63 (mean ± standard deviation [SD] 26.57 ± 10.56 versus 18.40 ± 12.05 for the Urticaria Activity Score of 7 days and 56.47 ± 23.78 versus 39.88 ± 25.44 for the Urticaria Activity Score of 3 weeks).

Conclusions: The CD63 expression on basophils appears as a reliable in vitro marker, useful in clinical practice in combination with autologous serum skin test to define chronic spontaneous urticaria patients with the highest urticaria activity that impairs a normal life.

No MeSH data available.


Related in: MedlinePlus

Box‐plots representing the severity of the disease, by positive and negative ASST and CD63 groups. Activity of the Urticaria was recorded at three different times: the day before (UAS), week before (UAS7), and 3 weeks before (UAS3w). This Figure shows UAS7 and UAS3w assessment by groups. Black horizontal line segment inside the box represents the median. Bottom and top box lines represent the 25th and the 75th percentiles, respectively.
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5134723&req=5

iid3125-fig-0001: Box‐plots representing the severity of the disease, by positive and negative ASST and CD63 groups. Activity of the Urticaria was recorded at three different times: the day before (UAS), week before (UAS7), and 3 weeks before (UAS3w). This Figure shows UAS7 and UAS3w assessment by groups. Black horizontal line segment inside the box represents the median. Bottom and top box lines represent the 25th and the 75th percentiles, respectively.

Mentions: Patients with positive ASST and whose sera induced CD63 expression on heterologous basophils showed significantly higher scores in UAS (mean ± SD 4.26 ± 1.84, P = 0.003), UAS7 (26.57 ± 10.56, P = 0.002), and UAS3w (61.87 ± 25.62, P = 0.001) than patients with negative ASST and CD63 results. Patients with positive ASST and positive CD63 expression by BAT showed higher UAS and UAS7 (P = 0.004 in both cases) and UAS3w (P = 0.001) than positive ASST and negative CD63 expression (ASST+/CD63‐ group: UAS 2.92 ± 1.75, UAS7 18.40 ± 12.05, UAS3w 39.88 ± 25.44) (Fig. 1). No significant differences on the UAS, UAS7, or UAS3w were observed just assessing positive ASST neither versus negative ASST patients nor versus positive ASST and negative patients once the expression of CD63 by BAT was negative. All the patients with positive BAT, except one were positive for ASST, resulting in a high specificity of 98.3%. However, only 31.6% of the serum of all the patients with positive ASST induced CD63 expression (sensitivity of 31.6%). In addition, all healthy donors sera (n = 9) showed a negative CD63 expression by BAT.


Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease
Box‐plots representing the severity of the disease, by positive and negative ASST and CD63 groups. Activity of the Urticaria was recorded at three different times: the day before (UAS), week before (UAS7), and 3 weeks before (UAS3w). This Figure shows UAS7 and UAS3w assessment by groups. Black horizontal line segment inside the box represents the median. Bottom and top box lines represent the 25th and the 75th percentiles, respectively.
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5134723&req=5

iid3125-fig-0001: Box‐plots representing the severity of the disease, by positive and negative ASST and CD63 groups. Activity of the Urticaria was recorded at three different times: the day before (UAS), week before (UAS7), and 3 weeks before (UAS3w). This Figure shows UAS7 and UAS3w assessment by groups. Black horizontal line segment inside the box represents the median. Bottom and top box lines represent the 25th and the 75th percentiles, respectively.
Mentions: Patients with positive ASST and whose sera induced CD63 expression on heterologous basophils showed significantly higher scores in UAS (mean ± SD 4.26 ± 1.84, P = 0.003), UAS7 (26.57 ± 10.56, P = 0.002), and UAS3w (61.87 ± 25.62, P = 0.001) than patients with negative ASST and CD63 results. Patients with positive ASST and positive CD63 expression by BAT showed higher UAS and UAS7 (P = 0.004 in both cases) and UAS3w (P = 0.001) than positive ASST and negative CD63 expression (ASST+/CD63‐ group: UAS 2.92 ± 1.75, UAS7 18.40 ± 12.05, UAS3w 39.88 ± 25.44) (Fig. 1). No significant differences on the UAS, UAS7, or UAS3w were observed just assessing positive ASST neither versus negative ASST patients nor versus positive ASST and negative patients once the expression of CD63 by BAT was negative. All the patients with positive BAT, except one were positive for ASST, resulting in a high specificity of 98.3%. However, only 31.6% of the serum of all the patients with positive ASST induced CD63 expression (sensitivity of 31.6%). In addition, all healthy donors sera (n = 9) showed a negative CD63 expression by BAT.

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: The basophil activation test showing CD63 up regulation could be a specific and sensitive in vitro complementary text to the in vivo autologous serum skin test for the activity assessment of the patients suffering autoimmune chronic spontaneous urticaria. The aim of this study is to define the basophil activation test as a useful tool in clinical practice in order to identify those patients with more active disease.

Methods: We screened 139 patients (96 women) diagnosed of chronic spontaneous urticaria using simultaneously autologous serum skin test and basophil activation test and their relationship with disease activity.

Results: Positive autologous serum skin test was found in 56.8%; from them, 31.6% were basophil activation test positive. Negative autologous serum skin test result was found in the 43.2% of the sample that showed negative CD63 expression results in all cases, except one. Patients with positive autologous serum skin test and positive CD63 by basophil activation test showed significant higher Urticaria Activity Score of 7 days (P = 0.004) and of 3 weeks (P = 0.001) than patients with positive autologous serum skin test and negative CD63 (mean ± standard deviation [SD] 26.57 ± 10.56 versus 18.40 ± 12.05 for the Urticaria Activity Score of 7 days and 56.47 ± 23.78 versus 39.88 ± 25.44 for the Urticaria Activity Score of 3 weeks).

Conclusions: The CD63 expression on basophils appears as a reliable in vitro marker, useful in clinical practice in combination with autologous serum skin test to define chronic spontaneous urticaria patients with the highest urticaria activity that impairs a normal life.

No MeSH data available.


Related in: MedlinePlus